Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial
2017 ASCO Annual MeetingNicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).
Related Videos
Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials
Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts o...
David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizuma...
Dean F. Bajorin, MD, and Peter H. O’Donnell, MD, on Urothelial Cancer: Results From Two KEYNOTE Trials
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findin...
Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib
Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to t...
Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers
Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembro...
